The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Phathom Pharmaceuticals Inc shares valued at $14,609 were purchased by Topper James N on May 21 ’25. At $3.86 per share, Topper James N acquired 3,780 shares. The insider’s holdings grew to 59,403 shares worth approximately $0.28 million following the completion of this transaction.
Also, Topper James N purchased 6,300 shares, netting a total of over 20,919 in proceeds. Following the buying of shares at $3.32 each, the insider now holds 55,623 shares.
Before that, Topper James N had added 1,120 shares to its account. In a trade valued at $3,543, the Director bought Phathom Pharmaceuticals Inc shares for $3.16 each. Upon closing the transaction, the insider’s holdings increased to 1,120 shares, worth approximately $0.23 million.
As published in their initiating research note from Cantor Fitzgerald on February 14, 2025, Phathom Pharmaceuticals Inc [PHAT] has been an Overweight and the price target has been revised to $23. Analysts at Stifel started covering the stock with ‘”a Buy”‘ outlook in a report released in early May. As of January 05, 2024, Needham has reiterated its “Buy” rating for PHAT. Earlier on August 09, 2023, H.C. Wainwright initiated its rating. Their recommendation was “a Buy” for PHAT stock.
Analyzing PHAT Stock Performance
During the last five days, there has been a surge of approximately 15.20%. Over the course of the year, Phathom Pharmaceuticals Inc shares have dropped approximately -42.12%. Shares of the company reached a 52-week high of $8.34 on 01/02/25 and a 52-week low of $2.21 on 05/08/25.
Support And Resistance Levels for Phathom Pharmaceuticals Inc (PHAT)
According to the 24-hour chart, there is a support level at 4.55, which, if violated, would cause prices to drop to 4.39. In the upper region, resistance lies at 4.92. The next price resistance is at 5.14. RSI (Relative Strength Index) is 59.00 on the 14-day chart, showing neutral technical sentiment.
